TA-8995: Its Use in Patients With Mild Dyslipidaemia (TULIP)

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 364 participants.

Also called NCT01970215

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 364 participants (enrolled count) (from the registry)
Sponsor
Xention Ltd (from the registry)
Registry
  • NCT NCT01970215
  • EudraCT 2012-005643-24
Other papers using this trial's data
  • Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial Lancet (London, England), 2015-08-01 DOI, PubMed 26047975
  • Comparison of low-density lipoprotein cholesterol equations in patients with dyslipidaemia receiving cholesterol ester transfer protein inhibition European heart journal. Cardiovascular pharmacotherapy, 2023-02-02 DOI, PubMed 36307922, PMC9892865 In the PMC Open Access subset under CC BY-NC.
  • Effects of the cholesteryl ester transfer protein inhibitor, TA-8995, on cholesterol efflux capacity and high-density lipoprotein particle subclasses Journal of clinical lipidology, 2016 DOI, PubMed 27678430

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Denmark, Netherlands (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01970215. Randomized; quadruple masking; primary purpose treatment. Start 2013-08 (registry gives no type); primary completion 2014-07 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
TA-8995: Its Use in Patients With Mild Dyslipidaemia (TULIP)
Acronym
TULIP
Condition
Dyslipidemia
Intervention (Drug)
TA-8995
Intervention (Drug)
Atorvastatin
Intervention (Drug)
Rosuvastatin
Intervention (Drug)
TA-8995 0mg (placebo)
Intervention (Drug)
Placebo Statin
Lead sponsor
Xention Ltd (class: industry)

Record details

Record id
cardio:ct-nct01970215
Content hash
fdadd3ada41d3fe0a9105ea10b39389d7301aadbaa3e2f99ec0426fe52195f09